不能摄取<sup>131</sup>I的甲状腺癌转移灶的<sup>131</sup>I-hTgMcAb显像及初步治疗

高克加; 沈江帆; 张乃康; 陶嵘; 王建华; 叶智卫; 赵林妹; 张光正; 马寄晓

doi:null

您当前的位置：

首页 >

文章列表页 >

不能摄取¹³¹I的甲状腺癌转移灶的¹³¹I-hTgMcAb显像及初步治疗

更新时间：2021-03-12

- 不能摄取¹³¹I的甲状腺癌转移灶的¹³¹I-hTgMcAb显像及初步治疗
- Preliminary imaging and therapy study of ¹³¹I-hTgMcAb in thyroid cancer metastasis which can not accumulate ¹³¹I
- 核技术 2005年第1期
- 作者机构：
  
  1. 上海市黄浦区中心医院核医学科
  2. 上海市普陀区中心医院核医学科
  3. 上海市第六人民医院核医学科,上海,200002
  4. ,上海,200233
- 作者简介：
- 基金信息：
- DOI：
  中图分类号： R736.1
- 纸质出版日期：2005-01-01
- 稿件说明：
移动端阅览
[1]高克加,沈江帆,张乃康,陶嵘,王建华,叶智卫,赵林妹,张光正,马寄晓.不能摄取~(131)I的甲状腺癌转移灶的~(131)I-hTgMcAb显像及初步治疗[J].核技术,2005(01):46-50.

GAO Kejia1 SHEN Jiangfan2 ZHANG Naikang2 TAO Rong2 WANG Jianhua1 YE Zhiwei1 ZHAO Linmei1 ZHANG Guangzheng2 MA Jixiao3 1. Preliminary imaging and therapy study of ¹³¹I-hTgMcAb in thyroid cancer metastasis which can not accumulate ¹³¹I[J]. Nuclear techniques, 2005, (1): 46-50.
[1]高克加,沈江帆,张乃康,陶嵘,王建华,叶智卫,赵林妹,张光正,马寄晓.不能摄取~(131)I的甲状腺癌转移灶的~(131)I-hTgMcAb显像及初步治疗[J].核技术,2005(01):46-50. DOI：

GAO Kejia1 SHEN Jiangfan2 ZHANG Naikang2 TAO Rong2 WANG Jianhua1 YE Zhiwei1 ZHAO Linmei1 ZHANG Guangzheng2 MA Jixiao3 1. Preliminary imaging and therapy study of ¹³¹I-hTgMcAb in thyroid cancer metastasis which can not accumulate ¹³¹I[J]. Nuclear techniques, 2005, (1): 46-50. DOI：

摘要

对不能摄取I的分化型、低分化型和未分化型甲状腺癌转移灶患者

采用I-hTgMcAb进行显像和131初步治疗

观察诊断转移灶和治疗价值。动物实验取无菌、无致热源的I-hTgMcAb

18.5MBq（131I）/50μg131（hTgMcAb）/kg静脉注射于新西兰实验兔

观察一个月

了解I-hTgMcAb的稳定性、安全性及体内代谢。131临床诊断26例上述各型甲状腺癌转移患者静脉滴注I-hTgMcAb稀释液。经多时相SPECT显像测定肿瘤与131正常组织之比（T/N）。分析治疗后4个月的I显像、X片、99mTc-MIBI显像等进行疗效对照及随访肝肾功131能、血常规、血小板、出、凝血时间。实验兔在静脉注射后6h内显像

见心腔、大血管显影

隐见肝区显影

但未见甲状腺、胃显影。经显像及治疗的26例甲状腺癌转移者I-hTgMcAb不同程度地浓聚于X摄片或CT131定位的转移灶部位

未感不良反应。131I-hTgMcAb进入转移灶的最高峰时间在72h左右。有5例患者的转移灶轻度缩小

17例患者的转移灶未见增大或增多。动物试验提示131I-hTgMcAb稳定性较好

未见有明显的毒性反应。对了解甲状腺癌转移灶的存在与治疗有一定的临床应用价值。

Abstract

Aim of this work is to evaluate the diagnostic and prospective value of 131I-hTgMcAb for the differential

low differential and other type of thyroid cancer which do not uptake 131I. New Zealand rabbits were IV with asepsis and pyrogen-free 131I-hTgMcAb (18.5 mBq/kg) in order to study the stability

safety and metabolism in vivo. 26 cases of thyroid cancer with metastasis were IV 131 I-hTgMcAb. Multiple-phase SPECT imaging was done and the radioactive ratios of T/N were determined. We compared the 131I imaging

X-ray photos

99mTc -MIBI imaging before and after 4 month therapy to evaluate the therapy effect. The liver and kidney function was followed up. The animal experiment showed that the cardiac chambers and great blood vessels could be imaged in 6 h

the liver was faintly visualized

while thyroid and stomach were not displayed. 26 cases showed 131I-hTgMcAb accumulated in the metastasis lesions which were identified by X-ray films or CT studies. The peak uptake time is about 72 h

the T/N ratio is over 4. After 4 months follow-up

the lesions of 5 cases became smaller

no changes in 17 cases. It is concluded that the stability of131I-hTgMcAb is good

no obvious side effects are found

so 131I-hTgMcAb is helpful to localize and treat the thyroid cancer.

关键词

Keywords

references

浏览量

117

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

⁹⁹Tc^m-angiostatin的体内分布及其与新生血管作用的实验研究

烟碱乙酰胆碱受体（nAChRs）显像化合物的研究进展

⁶⁷Ga肺肿瘤显像及其临床价值

不能摄取131I的甲状腺癌转移灶的131I-hTgMcAb显像及初步治疗

Preliminary imaging and therapy study of 131I-hTgMcAb in thyroid cancer metastasis which can not accumulate 131I

DOI：

摘要

Abstract

关键词

Keywords

references

不能摄取¹³¹I的甲状腺癌转移灶的¹³¹I-hTgMcAb显像及初步治疗

Preliminary imaging and therapy study of ¹³¹I-hTgMcAb in thyroid cancer metastasis which can not accumulate ¹³¹I